Canopy Growth (TSX:WEED) Falls 11% and Hits 52-Week Low

Canopy Growth (TSX:WEED)(NYSE:CGC) saw shares continue to drop on Dec. 20, falling by 11% to hit a share price not seen since 2017!

Canopy Growth (TSX: WEED)(NYSE:CGC) shares hit a new 52-week low on Dec. 20, falling about 11% to $11 per share as of writing. This comes after the company continues to make announcements that haven’t been positive for the company.

What happened?

The latest fall is likely tied to multiple factors. First, Canopy Growth announced last week that it would divest its subsidiary business, C³ Cannabinoid Compound Company GmbH, to German company Dermapharm Holding. The divestiture will aid Canopy Growth in “significantly reducing short-term capital investment requirements” by over $50 million, the statement read.

The transaction is expected to close in January of next year, bringing in around $115.5 million in upfront payment. This will be in addition to an earnout payment of around $61.4 million.

But it remains that cannabis stocks like Canopy Growth are in a very volatile industry. Supply chain demand has hurt every sector, and cannabis isn’t an exception. The Black Market also continues to weigh on growth, both in Canada and the United States. Furthermore, inflation risks may turn away even more potential customers. All while the S&P/TSX Composite Index continues to fall.

So what?

All of these risk factors make for a very risky situation for Canopy Growth investors. Shares may have hit 52-week lows, but it’s also the lowest share price since around September 2017! That includes the market selloff during March 2020.

Several reasons add up to the lower share price. There was the shakeup of the company’s executive team, and the continuing poor earnings led to even more of a selloff. Canopy Growth has yet to become profitable, despite continuously stating it remains focused on profitability.

During its latest earnings report, it announced that while it made some strong acquisitions and new product updates, it also saw net revenue go down by 3% year over year. Yet management stated it should “win” as the “industry matures.”

Now what?

It may take some time to reach that maturity. Canopy Growth remains a volatile company hedging itself on United States legalization. That could be some time off, considering the market risks and pandemic weighing on the economy. It’s unlikely there will be a sudden explosion of cannabis legislation in the next year or more.

So, if you’re a patient investor with Canopy Growth on hand, sure you can wait. But I wouldn’t necessarily see this drop as an opportunity. Unfortunately, things could become even worse for Canopy Growth in the near future, instead of better.

Shares of Canopy Growth are down 71% year to date after falling 11% on Dec. 20.

Fool contributor Amy Legate-Wolfe owns Canopy Growth Corp. The Motley Fool has no position in any of the stocks mentioned.

More on Cannabis Stocks

Medicinal research is conducted on cannabis.
Cannabis Stocks

Top Canadian Stocks to Buy Right Now With $1,000

Cannara, Source Energy and CareRx just updated investors. See what $1,000 can buy in these Canadian stocks, plus the risks…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Stocks for Beginners

This Cannabis Stock Jumped 12% in a Day: The Math Says Be Careful

Tilray's record revenue came with declining cannabis sales and negative free cash flow, making the investment much more speculative than…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Curaleaf’s Takeover Bid for Aurora Cannabis: What Investors Need to Know

Curaleaf's takeover bid for Aurora Cannabis offers a premium but brings stock, debt, and deal risks. Here’s what ACB investors…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Curaleaf Just Announced a Hostile Takeover Bid for Aurora Cannabis. Here’s What This Means for Investors.

It's appealing directly to the Canadian company's shareholders with a cash-and-stock offer.

Read more »

runner checks her biodata on smartwatch
Cannabis Stocks

Average TFSA and RRSP Balances at Age 45: Are You on Par?

Most 45-year-olds have less than $100,000 combined in their TFSA and RRSP. Here's how TerrAscend could help you close the…

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Risky Stocks That Could Send Your $100,000 Investment to $0

Cannabis stocks look risky because price wars, dilution, and regulation can turn one weak quarter into a long drawdown.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

My Biggest Investing Regret in 2025 Was Buying This Stock

Canopy Growth is a cautionary reminder to buy businesses, not headlines, especially in hype-driven sectors like cannabis.

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Popular Stocks That Could Wipe Out a $100,000 Nest Egg

Aurora Cannabis (TSX:ACB) is one stock that could wipe out your nest egg.

Read more »